Skip to main content

Crispr Therapeutics AG Value Stock - Dividend - Research Selection

Crispr therapeutics

ISIN: CH0334081137 , WKN: A2AT0Z

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

2025-02-13
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts signal growth. Click for my CRSP update.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

2025-02-10
CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

2025-02-10
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN). CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals.

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

2025-02-07
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

CRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025

2025-02-07
We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most contentious figures. She founded ARK Investment Management around ten […]

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

2025-02-06
Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

2025-02-05
CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ETCompany ParticipantsSamarth Kulkarni -...

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

2025-02-05
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising partnerships. Click for my CRSP stock update.

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2024 Update

2025-02-04
ARK Invest's 13F portfolio value increased by ~10% to ~$12B this quarter. Check out the top holdings and new stakes of the portfolio.

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

2025-02-04
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.